Published in J Virol on August 01, 1995
Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade C. J Virol (2004) 1.14
Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoprotein. J Virol (2000) 1.07
Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J Virol (2002) 0.95
Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype. J Virol (1999) 0.93
Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates. J Virol (1998) 0.91
Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res (2010) 0.86
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens. Clin Diagn Lab Immunol (1998) 0.84
Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody. Retrovirology (2010) 0.83
Feline immunodeficiency virus (FIV) neutralization: a review. Viruses (2011) 0.80
Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus. J Virol (2007) 0.78
Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies. PLoS One (2013) 0.78
Domestic cat microsphere immunoassays: detection of antibodies during feline immunodeficiency virus infection. J Immunol Methods (2013) 0.75
Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science (1987) 6.56
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res (1988) 3.89
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol (1990) 2.40
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol (1992) 1.94
Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science (1984) 1.77
The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol (1990) 1.76
Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J Acquir Immune Defic Syndr (1991) 1.75
Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. J Virol (1994) 1.59
Feline immunodeficiency virus: a neurotropic lentivirus. J Acquir Immune Defic Syndr (1990) 1.59
Structure and variations of feline immunodeficiency virus envelope glycoproteins. Virology (1993) 1.41
Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol (1994) 1.41
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol (1990) 1.29
Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol (1993) 1.28
Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function. AIDS Res Hum Retroviruses (1990) 1.19
A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol (1993) 1.16
Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. J Virol (1992) 1.15
Decline in CD4+ cell numbers in cats with naturally acquired feline immunodeficiency virus infection. J Virol (1992) 1.14
Feline immunodeficiency virus is a lentivirus associated with an AIDS-like disease in cats. AIDS (1989) 1.13
Hematologic manifestations of feline immunodeficiency virus infection. Blood (1990) 1.10
Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology (1994) 1.06
Comparison of early and late feline immunodeficiency virus encephalopathies. AIDS (1992) 1.05
Neutralizing antibodies in cats infected with feline immunodeficiency virus. J Clin Microbiol (1993) 0.98
Insertion of N-linked glycosylation sites in the variable regions of the human immunodeficiency virus type 1 surface glycoprotein through AAT triplet reiteration. J Virol (1994) 0.93
Two different mutations in the envelope protein of feline immunodeficiency virus allow the virus to escape from neutralization by feline serum antibodies. Vet Immunol Immunopathol (1995) 0.82
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 16.30
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
A pandemic warning? Nature (1997) 8.70
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill (2012) 7.96
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol (2000) 6.96
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods (1998) 3.67
Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) (2003) 3.16
Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill (2013) 2.97
Identification of two homologs of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species. J Virol (1997) 2.91
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Influenza B virus in seals. Science (2000) 2.70
Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol (2003) 2.64
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine (2006) 2.59
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol (2008) 2.24
Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol (2000) 2.21
Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine (1998) 2.17
Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol (2000) 2.11
Haemorrhagic fever with renal syndrome. Lancet (1993) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. J Gen Virol (1996) 2.06
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol (2002) 2.05
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol (2000) 1.95
Influenza types and patient population. Lancet (1995) 1.94
Influenza A virus surveillance in wild birds in Northern Europe in 1999 and 2000. Avian Dis (2003) 1.93
Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype. Lancet (2000) 1.87
Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant (2007) 1.83
Avian influenza viruses in mammals. Rev Sci Tech (2009) 1.79
Immune responses to influenza virus infection. Virus Res (2011) 1.70
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol (2005) 1.67
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother (2000) 1.66
Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis (1994) 1.65
Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol (2002) 1.63
Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol (2000) 1.61
Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol (1997) 1.61
Identification of virus causing recent seal deaths. Nature (1988) 1.58
Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol (2011) 1.57
Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine (1996) 1.55
Involvement of thiol enzymes in the lysosomal breakdown of native and denatured proteins. Biochim Biophys Acta (1973) 1.54
Prevalence and association between herpes simplex virus types 1 and 2-specific antibodies in attendees at a sexually transmitted disease clinic. Int J Epidemiol (2001) 1.53
PCBs are a health risk for humans and wildlife. Science (2000) 1.51
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. J Virol (2007) 1.50
The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. Euro Surveill (2014) 1.49
Canine distemper virus--a morbillivirus in search of new hosts? Trends Microbiol (1997) 1.49
Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine (2009) 1.47
Recommendations for the use of inactivated influenza vaccines and other preventive measures. Vaccine (2001) 1.47
Mass die-Off of Caspian seals caused by canine distemper virus. Emerg Infect Dis (2001) 1.46
Profiling of humoral immune responses to influenza viruses by using protein microarray. Clin Microbiol Infect (2011) 1.44
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
Herpes simplex virus type 1 (HSV-1)--induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1. Ann Neurol (2000) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol (1998) 1.39
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol (2001) 1.38
Role of individual cathepsins in lysosomal protein digestion as tested by specific inhibitors. Biochim Biophys Acta (1974) 1.38
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol (1995) 1.38
Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol (2011) 1.38
Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology (1983) 1.35
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies. Virus Res (1989) 1.34
An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol (1990) 1.34
Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles. J Clin Microbiol (2001) 1.34
The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis (2007) 1.34
Detection, typing, and subtyping of enteric adenoviruses 40 and 41 from fecal samples and observation of changing incidences of infections with these types and subtypes. J Clin Microbiol (1993) 1.31
Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands. Virology (2001) 1.30
Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones. J Immunol (1989) 1.29
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
Cellular and humoral responses to influenza in gabonese children living in rural and semi-urban areas. J Infect Dis (2007) 1.29
Pathogenesis of influenza virus infections: the good, the bad and the ugly. Curr Opin Virol (2012) 1.29
New clues to the emergence of flu pandemics. Nat Med (1998) 1.28
ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine (1999) 1.28
Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J Virol Methods (2000) 1.28
Purification and properties of a periplasmic D-xylose-binding protein from Escherichia coli K-12. J Biol Chem (1982) 1.28